Skip to main content
SpringerLink
Log in

Hormone Therapy (I): Estrogens, Progestogens, and Androgens

  • Chapter
  • First Online:
Menopause

Abstract

Most important ovarian hormones are estrogens, progestins, and androgens. Menopausal ovarian failure supposes a hormonal deprivation with variable repercussions for women, like symptomatology with negative effects on quality of life, and changes of future risks of some important and prevalent pathologies. Hormone therapy is the etiologic treatment for avoiding all of that, but introduces some modifications in those risks, and has collateral effects. In addition, many types of composition, formulations, doses, routes, and schemes are available for HT, with relevant differences on pharmacokinetics, efficacy, or collateral effects which can be even targets for selection, like bleeding pattern or lipid profile. So topics like information, indication, selection of HT, acceptance, and compliance are difficult in many cases and require knowledge and experience for the health-care provider. In this chapter, we review and discuss all of those topics, the treatment plan, and the follow-up questions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Brockie J, Lambrinoudaki I, Ceausu I, Depypere H, Erel CT, Pérez-López FR, Schenck-Gustafsson K, van der Schouw YT, Simoncini T, Tremollieres F, Rees M, European Menopause and Andropause Society. EMAS position statement: menopause for medical students. Maturitas. 2014;78(1):67–9.

    Article  PubMed  Google Scholar 

  2. de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C, Pierroz DD. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016;91:153–5.

    Article  PubMed  Google Scholar 

  3. Alexandersen P, Tanko LB. Algorithm for prescription of HRT or ERT for postmenopausal women. Climacteric. 2006;9(3):238–9.

    Article  CAS  PubMed  Google Scholar 

  4. Bastian LA, McBride CM, Fish L, Lyna P, Farrell D, Lipkus IM, et al. Evaluating participants’ use of a hormone replacement therapy decision-making intervention. Patient Educ Couns. 2002;48(3):283–91.

    Article  PubMed  Google Scholar 

  5. Castelo-Branco C, Ferrer J, Palacios S, Cornago S. The prescription of hormone replacement therapy in Spain: differences between general practitioners and gynaecologists. Maturitas. 2006;55(4):308–16.

    Article  PubMed  Google Scholar 

  6. Baber RJ, Panay N, Fenton A, IMS Writing Group. 2016 IMS recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109–50.

    Article  CAS  PubMed  Google Scholar 

  7. Rudy DR. Hormone replacement therapy. How to select the best preparation and regimen. Postgrad Med. 1990;88(8):157–60. 163-4

    Article  CAS  PubMed  Google Scholar 

  8. Purbrick B, Stranks K, Sum C, MacLennan AH. Future long-term trials of postmenopausal hormone replacement therapy—what is possible and what is the optimal protocol and regimen? Climacteric. 2012;15(3):288–93.

    Article  CAS  PubMed  Google Scholar 

  9. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril. 2001;75(6):1080–7.

    Article  CAS  PubMed  Google Scholar 

  10. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. Osteoporos Int. 2005;16(4):372–9.

    Article  CAS  PubMed  Google Scholar 

  11. Fenton A, Panay N. Hormone replacement therapy prescription: a disconnect between personal and patient prescribing. Climacteric. 2012;15(5):409–10.

    Article  PubMed  Google Scholar 

  12. Gambacciani M, Genazzani AR. Hormone replacement therapy: the benefits in tailoring the regimen and dose. Maturitas. 2001;40(3):195–201.

    Article  CAS  PubMed  Google Scholar 

  13. Mattsson LA, Skouby SO, Heikkinen J, Vaheri R, Maenpaa J, Timonen U. A low-dose start in hormone replacement therapy provides a beneficial bleeding profile and few side-effects: randomized comparison with a conventional-dose regimen. Climacteric. 2004;7(1):59–69.

    Article  CAS  PubMed  Google Scholar 

  14. Panay N, Fenton A. Alternative regimens for endometrial protection ? Where are we now? Climacteric. 2011;14(6):607–8.

    Article  PubMed  Google Scholar 

  15. Andersen ML, Alvarenga TF, Mazaro-Costa R, Hachul HC, Tufik S. The association of testosterone, sleep, and sexual function in men and women. Brain Res. 2011;1416:80–104.

    Article  CAS  PubMed  Google Scholar 

  16. Bachmann G, Bancroft J, Braunstein G, Burger H, Davis S, Dennerstein L, Goldstein I, Guay A, Leiblum S, Lobo R, Notelovitz M, Rosen R, Sarrel P, Sherwin B, Simon J, Simpson E, Shifren J, Spark R, Traish A, Princeton. Female androgen insufficiency: the Princeton consensus statement on definition, classification, and assessment. Fertil Steril. 2002;77(4):660–5.

    Article  PubMed  Google Scholar 

  17. Howell S, Shalet S. Testosterone deficiency and replacement. Horm Res. 2001;56(Suppl 1):86–92.

    CAS  PubMed  Google Scholar 

  18. Penotti M, Sironi L, Cannata L, Vigano P, Casini A, Gabrielli L, et al. Effects of androgen supplementation of hormone replacement therapy on the vascular reactivity of cerebral arteries. Fertil Steril. 2001;76(2):235–40.

    Article  CAS  PubMed  Google Scholar 

  19. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, Derzko C, Bearnson P, Kakos N, O'Neill S, Levine S, Wekselman K, Buch A, Rodenberg C, Kroll R. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 study. Menopause. 2006;13(5):770–9.

    Article  PubMed  Google Scholar 

  20. Gelfand MM, Wiita B. Androgen and estrogen-androgen hormone replacement therapy: a review of the safety literature, 1941 to 1996. Clin Ther. 1997;19(3):383–404.

    Article  CAS  PubMed  Google Scholar 

  21. Braunstein GD, Sundwall DA, Katz M, Shifren JL, Buster JE, Simon JA, Bachman G, Aguirre OA, Lucas JD, Rodenberg C, Buch A, Watts NB. Safety and efficacy of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. Arch Intern Med. 2005;165(14):1582–9.

    Article  CAS  PubMed  Google Scholar 

  22. Stute P, Becker HG, Bitzer J, Chatsiproios D, Luzuy F, von Wolff M, Wunder D, Birkhäuser M. Ultra-low dose—new approaches in menopausal hormone therapy. Climacteric. 2015;18(2):182–6.

    Article  CAS  PubMed  Google Scholar 

  23. Johansen OE, Qvigstad E. Rationale for low-dose systemic hormone replacement therapy and review of estradiol 0.5 mg/NETA 0.1 mg. Adv Ther. 2008;25(6):525–51.

    Article  CAS  PubMed  Google Scholar 

  24. Burch D, Bieshuevel E, Smith S, Fox H. Can endometrial protection be inferred from the bleeding pattern on combined cyclical hormone replacement therapy. Maturitas. 2000;34(2):155–60.

    Article  CAS  PubMed  Google Scholar 

  25. Keller PJ, Hotz E, Imthurn B. A transdermal regimen for continuous combined hormone replacement therapy in the menopause. Maturitas. 1992;15(3):195–8.

    Article  CAS  PubMed  Google Scholar 

  26. Simon JA. What’s new in hormone replacement therapy: focus on transdermal estradiol and micronized progesterone. Climacteric. 2012;15(Suppl 1):3–10.

    Article  CAS  PubMed  Google Scholar 

  27. Sulak PJ, Caubel P, Lane R. Efficacy and safety of a constant-estrogen, pulsed-progestin regimen in hormone replacement therapy. Int J Fertil Womens Med. 1999;44(6):286–96.

    CAS  PubMed  Google Scholar 

  28. Rees MC, Kuhl H, Engelstein M, Mattila L, Maenpaa J, Mustonen M. Endometrial safety and tolerability of triphasic sequential hormone replacement estradiol valerate/medroxyprogesterone acetate therapy regimen. Climacteric. 2004;7(1):23–32.

    Article  CAS  PubMed  Google Scholar 

  29. Cano A, Tarin JJ, Duenas JL. Two-year prospective, randomized trial comparing an innovative twice-a-week progestin regimen with a continuous combined regimen as postmenopausal hormone therapy. Fertil Steril. 1999;71(1):129–36.

    Article  CAS  PubMed  Google Scholar 

  30. Cameron ST, Critchley HO, Glasier AF, Williams AR, Baird DT. Continuous transdermal oestrogen and interrupted progestogen as a novel bleed-free regimen of hormone replacement therapy for postmenopausal women. Br J Obstet Gynaecol. 1997;104(10):1184–90.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hospital Universitario de San Juan de Alicante, Miguel Hernández University, Alicante, Spain

    Francisco Quereda

Authors
  1. Francisco Quereda
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francisco Quereda .

Editor information

Editors and Affiliations

  1. Department of Pediatrics, Obstetrics and Gynecology, University of Valencia, Valencia, Spain

    Antonio Cano

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Quereda, F. (2017). Hormone Therapy (I): Estrogens, Progestogens, and Androgens. In: Cano, A. (eds) Menopause. Springer, Cham. https://doi.org/10.1007/978-3-319-59318-0_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-59318-0_11

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-59317-3

  • Online ISBN: 978-3-319-59318-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation